DK0946550T3 - Fremstilling af [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-chlor-2-thienyl)methyl]propyl]amino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentancarboxamid - Google Patents

Fremstilling af [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-chlor-2-thienyl)methyl]propyl]amino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentancarboxamid

Info

Publication number
DK0946550T3
DK0946550T3 DK97950663T DK97950663T DK0946550T3 DK 0946550 T3 DK0946550 T3 DK 0946550T3 DK 97950663 T DK97950663 T DK 97950663T DK 97950663 T DK97950663 T DK 97950663T DK 0946550 T3 DK0946550 T3 DK 0946550T3
Authority
DK
Denmark
Prior art keywords
dihydroxycyclopentanecarboxamide
imidazo
pyridin
thienyl
chloro
Prior art date
Application number
DK97950663T
Other languages
Danish (da)
English (en)
Inventor
Michael K O'brien
Patrick Leon
Ching T Tsuei
Benoit J Vanasse
Herve Garcia
Tory H Powner
Laurence W Reilly
Harshavadan C Shah
Michael D Thompson
Francis L Walther
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK0946550T3 publication Critical patent/DK0946550T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DK97950663T 1996-12-11 1997-11-24 Fremstilling af [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-chlor-2-thienyl)methyl]propyl]amino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentancarboxamid DK0946550T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3276496P 1996-12-11 1996-12-11
PCT/US1997/021439 WO1998025921A1 (en) 1996-12-11 1997-11-24 PREPARATION OF [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-CHLORO-2-THIENYL) METHYL]PROPYL]AMINO]-3H-IMIDAZO[4,5-b]PYRIDIN-3-yl]-N-ETHYL-2,3-DIHYDROXYCYCLOPENTANECARBOXAMIDE

Publications (1)

Publication Number Publication Date
DK0946550T3 true DK0946550T3 (da) 2005-08-29

Family

ID=21866680

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97950663T DK0946550T3 (da) 1996-12-11 1997-11-24 Fremstilling af [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-chlor-2-thienyl)methyl]propyl]amino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentancarboxamid

Country Status (27)

Country Link
US (2) US6143894A (es)
EP (2) EP1609791A1 (es)
JP (1) JP2001506626A (es)
KR (4) KR100510389B1 (es)
CN (3) CN1191251C (es)
AP (1) AP1063A (es)
AT (1) ATE301120T1 (es)
AU (1) AU738581B2 (es)
BG (1) BG63805B1 (es)
BR (1) BR9713705A (es)
CA (1) CA2274630C (es)
DE (1) DE69733897T2 (es)
DK (1) DK0946550T3 (es)
EA (1) EA001989B1 (es)
ES (1) ES2242984T3 (es)
HK (2) HK1023998A1 (es)
HU (1) HUP0000342A3 (es)
IL (1) IL130397A (es)
MX (1) MXPA03006730A (es)
NO (2) NO319722B1 (es)
OA (1) OA11061A (es)
PT (1) PT946550E (es)
SI (1) SI0946550T1 (es)
SK (1) SK71199A3 (es)
UA (1) UA54479C2 (es)
WO (1) WO1998025921A1 (es)
ZA (1) ZA9711035B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1140933T1 (en) 1998-12-31 2005-02-28 Aventis Pharmaceuticals Inc. Process for preparing n6-substituted deaza-adenosine derivatives
US7291603B2 (en) * 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
FR2846656B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2505085B2 (ja) * 1990-09-25 1996-06-05 ローヌ−プーラン ローラー インターナショナル （ホウルディングス） インコーポレイテッド 抗昇圧および抗虚血特性を有する化合物
AU746706B2 (en) * 1997-07-03 2002-05-02 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
EA003645B1 (ru) * 1998-12-21 2003-08-28 Авентис Фармасьютикалз Инк. Способ получения n6-замещенных производных деаза-аденозина

Also Published As

Publication number Publication date
NO20052327L (no) 1999-08-10
CN1090630C (zh) 2002-09-11
AP1063A (en) 2002-04-26
PT946550E (pt) 2005-09-30
HK1023998A1 (en) 2000-09-29
MXPA03006730A (es) 2003-10-24
US6143894A (en) 2000-11-07
KR20050046793A (ko) 2005-05-18
UA54479C2 (uk) 2003-03-17
WO1998025921A1 (en) 1998-06-18
IL130397A (en) 2005-11-20
BR9713705A (pt) 2000-05-09
NO319722B1 (no) 2005-09-05
BG63805B1 (bg) 2003-01-31
EP0946550A4 (en) 2003-05-14
DE69733897T2 (de) 2006-06-01
AU5360798A (en) 1998-07-03
KR20060002030A (ko) 2006-01-06
EP0946550A1 (en) 1999-10-06
OA11061A (en) 2002-02-27
BG103484A (en) 2000-06-30
NO992795L (no) 1999-08-10
KR20000057505A (ko) 2000-09-15
IL130397A0 (en) 2000-06-01
CN1394859A (zh) 2003-02-05
NO992795D0 (no) 1999-06-09
EA001989B1 (ru) 2001-10-22
CA2274630C (en) 2000-10-03
CN1240445A (zh) 2000-01-05
SK71199A3 (en) 2000-07-11
SI0946550T1 (en) 2005-10-31
EA199900527A1 (ru) 2000-02-28
CN1191251C (zh) 2005-03-02
HUP0000342A3 (en) 2001-01-29
ATE301120T1 (de) 2005-08-15
AP9901550A0 (en) 1999-06-30
KR100571690B1 (ko) 2006-04-18
AU738581B2 (en) 2001-09-20
NO20052327D0 (no) 2005-05-12
KR100510389B1 (ko) 2005-08-31
KR20060002029A (ko) 2006-01-06
ES2242984T3 (es) 2005-11-16
JP2001506626A (ja) 2001-05-22
US6235909B1 (en) 2001-05-22
ZA9711035B (en) 1998-06-15
CN1660842A (zh) 2005-08-31
DE69733897D1 (de) 2005-09-08
EP0946550B1 (en) 2005-08-03
HUP0000342A2 (hu) 2000-10-28
EP1609791A1 (en) 2005-12-28
HK1051862A1 (en) 2003-08-22

Similar Documents

Publication Publication Date Title
ATE251623T1 (de) Imidazo(1,2-a)pyridin- und pyrazolo(2,3- a)pyridinderivate
PT1140939E (pt) 2-aril-3-(heteroaril)- imidazo [1,2-alfa] pirimidinas substituidas, e formulacoes farmaceuticas e metodos relacionados
NO984082D0 (no) Pyrimido£5,4-d|pyrimidiner, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte for fremstilling derav
ATE214704T1 (de) 5h-thiazolo(3,2-a)pyrimidinderivate
IS4570A (is) Imidazó[1,2-a]pýridín afleiður
EE200000113A (et) 2,3-diarüülpürasolo[1,5-b]püridasiini derivaadid, nende valmistamine ja kasutamine tsüklooksügenaas 2 (COX-2) inhibiitoritena
EE05181B1 (et) Prasolo[4,3-d]primidiini derivaadid, neid sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja meetodid nende valmistamiseks
PT769965E (pt) Formulacoes aquosas de risperidona
NO984081D0 (no) Pyrimido£5,4-d|pyrimidiner, medikamenter inneholdende disse forbindelser, deres anvendelse og fremgangsmÕte for fremtilling derav
DK0931081T3 (da) Pyridazino-[4,5-B]-quinolin-5-oxid-derivater, deres fremstilling og deres anvendelse som glycinantagonister
BR9711724A (pt) Derivado de 3,4,5,6,7,8-hexaidro-pirido (4',3':4,5)tieno-(2,3-d) pirimidina 3-substitu¡da e uso do mesmo
BR9611628A (pt) Derivados de pirido [2,3-d] pirimidina e composições medicinais dos mesmos
FR2832711B1 (fr) Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
FR2754262B1 (fr) Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
NO20000605D0 (no) 3-Substituerte 3,4,5,7-tetrahydro-pyrrolo[3',4':4,5]tieno[2,3- D]pyrimidinderivater, deres fremstilling og anvendelse som 5HT- antagonister
DK0946550T3 (da) Fremstilling af [1S-[1a,2b,3b,4a(S*)]]-4-[7-[[1-(3-chlor-2-thienyl)methyl]propyl]amino]-3H-imidazo[4,5-b]pyridin-3-yl]-N-ethyl-2,3-dihydroxycyclopentancarboxamid
NO996045L (no) 3-Substituerte pyrido[3',4':4,5]tieno[2,3-d]pyrimidin- derivater, fremstilling og anvendelse derav
NO20000183L (no) 5-substituerte-3-oksadiazolyl-1,6-naftyridin-2(1H)-on- derivater
EE9400439A (et) Naftüridiini derivaadid, nende valmistamise meetodid, neid sisaldavad ravimvormid, eriti kasutamiseks antiproliferatiivsete preparaatidena
FR2761073B1 (fr) Derives de pyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
FR2783828B1 (fr) Derives d'acide 5,6-dihydro-4h-imidazo[1,2-a][1] benzazepine -1-acetique, leur preparation et leur application en therapeutique
BR1100681A (pt) Derivados condensados da imidazopiridina
IL152921A0 (en) Preparation of [1s-[alpha, 2beta, 3beta, 4alpha(s*)]]-4-[7-[[1-3-chloro-2-thienyl) methyl] propyl] amino]-3h-imidazo[4,5-b]pyridin-3-yl-]-n-ethyl-2, 3 dihydroxycyclopentanecarboxamide
ID19779A (id) Pembuatan (7s,trans)-2-(2-pirimidinil)-7-(hidroksimetil) oktahidro-2h-pirido [1,2-a] pirazin